was 27.9 months (range: 3.3-114.6). Median PSA prior to initiation of ADT was 18 ng/mL (range: 0.61-2940). 72.3% of patients achieved a 1year mean T < 20 ng/dl; 18.6% achieved 20-32 ng/dl; 5.4% achieved 32-50 ng/dl; and 3.6% achieved > 50 ng/dl. There was no statistically significant difference in progression-free survival between patients with different levels of 1-year mean testosterone values (log-rank p¼0.813).
INTRODUCTION AND OBJECTIVES: Studies have shown that systemic chemotherapy can improve survival in patient who develop castration resistant prostate cancer. We evaluate the time to chemotherapy from initiation of ADT by racial subgroups in men with prostate cancer.
METHODS: We identified 81,579 men diagnosed with prostate cancer between 2004-2009 from the Surveillance, Epidemiology and End Results database (SEER). We then risk stratified the men based on the DAmico criteria. Those with one or more unknown tumor variables (prostate specific antigen, T stage and/or Gleason Score) were labeled unknown. Of this group, we identified 2370 men who received chemotherapy after ADT, 2137 non-Hispanic Caucasian and non-Hispanic 233 African American. Overall and risk-stratified analyses were performed using T-test and multiple linear regression which compared the time interval from diagnosis to chemotherapy and from initiation of ADT to initiation of chemotherapy in African Americans vs. Caucasians.
RESULTS: The median time from diagnosis to chemotherapy was 32 months and from initiation of ADT to chemotherapy was 25 months. The median time from ADT to chemotherapy for the low risk group was 16 months (n¼ 119), intermediate risk was 29 months (n ¼ 313), high risk 29 months (n ¼ 920) and unknown 21 months (n ¼ 1018). African American males had a median length of 18 months compared to Caucasian males 25 months (p value from t-test ¼ 0.006). After adjusting for age, year of diagnosis, income, education, Charlson comorbidity score, and risk of prostate cancer, the difference is still significant: the least squares mean time from ADT to chemo is 22.5 months in AA vs. 27.5 months in CA (p¼0.006).
CONCLUSIONS: The length of time from ADT to salvage chemotherapy in African American males is shorter compared to Caucasian males. This may suggest that AA men have cancers that progress faster on ADT compared to prostate cancer in Caucasian men. 1-107 months). We find high individualised variabilty in TT recovery.-Recovery over castration levels: 25% of patients do not recover. Our intervals of recovery for 25, 50, 75 and 100% of recoverer patients are 4, 7, 10 and 42 months.-Recovery over eugonadic levels: 84% of patients do not normalize TT. After 12 months of ADT withdrawal only 8% of patients recovered normal levels, the maximum rate of recovery is at 32 months, no one patient recovered later on. In multivariate analysis "duration of ADT" and "age at ADT withdrawal" are significant predictors (H.R: 0.69, p¼0.0002 and HR: 0.44, p<0.0001, for 0.5-Recovery; and HR:0.45,p¼0.0006 and HR:0.39,p¼0.0002, for 3.5-Recovery). We build two nomograms of recovery at 1, 2 and 3 years, with light overestimation for intermediate values in calibration analysis and a discrimination capacity ('c index') of 0.709 and 0.723, with AUC of 0.778, 0.813 and 0.805, and 0.707, 0.788 and 0.811 at 1, 2, and 3 years, respectively. CONCLUSIONS: We confirmed a high variability in TT recovery after ADT withdrawal. We found as the most relevant predictors "duration of ADT" and "age at ADT withdrawal". We obtained accurate calibrated and discriminative predictive nomograms of castration and eugonadic recovery. Those models would allow us to estimate and counsell functional recovery after adjuvant therapy, and to keep castration after ADT withdrawal or intermittency in a more cost-effectiveness practice. . 197, No. 4S, Supplement, Sunday, May 14, 2017 
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